VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA).

The discussion provided greater clarity on the clinical development path for BL1243. If successfully developed and approved, BL1243 could offer a differentiated oral treatment option for patients with dry AMD. The program is part of Bausch + Lomb’s robust pipeline and underscores the company’s commitment to advancing the standard of care in eye health.

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Business Wire